Notorious pharma exec Martin Shkreli is downplaying the success of high school students who recreated his $750 life-saving medication for just $2, saying “anyone can make any drug” and denying he got “owned” by the junior scientists.

“Glad the kids are learning about science,” Shkreli posted on Twitter early Thursday. “Not sure how anyone got ‘owned’ lol.”

Shkreli — dubbed the “most hated man in the world” last year after jacking up the price of anti-parasitic drug Daraprim from $13 to $750 per pill overnight – was responding to messages celebrating the feat by 11 chemistry students from Sydney Grammar School under the guidance of Dr. Alice Williamson from the University of Sydney.

Shkreli told another Twitter user that “anyone can make any drug” – claiming it to be “pretty ez” – and said the project didn’t show him up at all.

“lol how is that showing anyone up?” he posted Wednesday. “Almost any drug can be made at small scale for a low price. Glad it makes u feel good tho.”

Shkreli also said “small scale synthesis” of the drug doesn’t equal “new competition as some foolishly suggested” in an earlier post earlier Thursday. In another, he derogatorily referred to commenters as “geniuses” and extolled the merits of being prosperous.

“Congratulations on a crash course in organic chemistry and good luck with FDA approval.”

“Is there something wrong with being successful?” Shkreli replied to a reporter for the Guardian Australia. “I understand your line of work doesn’t pay well, but don’t take it out on me.”

Williamson said the students “shared the outrage of the general public” toward Shkreli, giving their work additional focus. After starting with 17 grams of raw material available online, the students worked with their chemistry teacher, Dr. Malcolm Binns, and produced 3.7 grams of Daraprim.

“That’s about $110,000 worth of the drug,” Williamson told the Sydney Morning Herald, adding that 50 tablets of the drug can be purchased for $13 in Australia.

To be exact, that’s about $1.48 per pill in the US, depending on the exchange rate, Forbes.com reports.

Williamson told the Washington Post she hopes the project sends a “clear” message to pharmaceutical companies.

“How can you get away with charging $750 for an essential medicine to so many people who are already vulnerable?” she asked.

James Wood, a 17-year-old student who participated in the project, said he didn’t believe Shkreli’s justification for the mammoth price hike, saying the excuse of extracting more money from insurance companies felt a “bit wishy-washy,” he told the Sydney Morning Herald.

“He was clearly trying to justify something driven by the profit motive,” Wood told the newspaper.

Shkreli did not return requests for comment from The Post early Thursday.

Other Twitter users, meanwhile, didn’t miss their chance to take shots at the former Turing Pharmaceutical chief executive.

“Man, you really are a sad little man,” one post read.

Shkreli, for his part, offered a seemingly sarcastic response when contacted by The Post regarding the students’ accomplishment.

“Congratulations on a crash course in organic chemistry and good luck with FDA approval,” Shkreli told The Post through spokesperson Alan Ripp.

Did pharma bro, Martin Shkreli, get what he deserved?